Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA requested that Merck conduct an additional study in primates during its review of Januvia (sitagliptin) due to concerns of necrotoxicity based on similar findings seen with other DPP-4 inhibitors.